Mutations in APOA-I and ABCA1 in Norwegians with low levels of HDL cholesterol

Clinica Chimica Acta

Volumn 411, Issue 23-24, 2010, Pages 2019-2023

  Berge, Knut Erik ^a   Leren, Trond P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

ABCA1 gene; ApoA I gene; HDL cholesterol; Ischemic heart disease; Mutation

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA SEQUENCE; FAMILY HISTORY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; HETEROZYGOSITY; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID METABOLISM; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; NORWAY; NUCLEOTIDE SEQUENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR;

ADULT; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL, HDL; CODON, NONSENSE; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HETEROZYGOTE; HUMANS; MALE; MUTATION; MUTATION, MISSENSE; MYOCARDIAL ISCHEMIA; NORWAY; PEDIGREE; RNA SPLICE SITES;

EID: 77957749592     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.08.027     Document Type: Article

References (27)

1. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
2. Tall A.R. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008, 263:256-273.
3. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006, 116:3090-3100.
4. Tall A.R., Breslow J.L., Rubin E.M., Brewer H.B. Genetic disorders affecting plasma high-density lipoproteins. The metabolic basis of inherited disease 2001, 2915-2936. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
5. Assmann G., von Eckardstein A., Brewer H.B. Familial analphalipoproteinemia: Tangier disease. The metabolic basis of inherited disease 2001, 2937-2960. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
6. Santamarina-Fojo S., Hoeg J.M., Assmann G., Brewer H.B. Lecithin cholesterol acyltransferase deficiency and fish eye disease. The metabolic basis of inherited disease 2001, 2817-2833. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
7. Qasim A., Rader D.J. Human genetics of variation in high-density lipoprotein cholesterol. Curr Atheroscler Rep 2006, 8:198-205.
8. Calabresi L., Baldassarre D., Castelnuovo S., et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 2009, 120:628-635.
9. Genest J.J., Martin-Munley S.S., McNamara J.R., et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992, 85:2025-2033.
10. Hovingh G.K., de Groot E., van der Steeg W., et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 2005, 16:139-145.
11. Frikke-Schmidt R., Nordestgaard B.G., Stene M.C., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008, 299:2524-2532.
12. Serfaty-Lacrosniere C., Civeira F., Lanzberg A., et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994, 107:85-98.
13. Franceschini G., Sirtori C.R., Capurso A., Weisgraber K.H., Mahley R.W. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980, 66:892-900.
14. Reaven G.M. Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab 2005, 1:9-14.
15. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
16. den Dunnen J.T., Antonarakis E. Nomenclature for the description of human sequences. Hum Genet 2001, 109:121-124.
17. Cohen J.C., Kiss R.S., Pertsemlidis A., Marcel Y.L., McPherson R., Hobbs H.H. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004, 305:869-872.
18. Frikke-Schmidt R., Nordestgaard B.G., Jensen G.B., Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 2004, 114:1343-1353.
19. Brousseau M.E., Schaefer E.J., Dupuis J., et al. Novel mutations in the gene encoding ATP-binding cassette 1 in four Tangier disease kindreds. J Lipid Res 2000, 41:433-441.
20. Ishii J., Nagano M., Kujiraoka T., et al. Clinical variant of Tangier disease in Japan: mutation of the ABCA1 gene in hypoalphalipoproteinemia with corneal lipidosis. J Hum Genet 2002, 47:366-369.
21. Oslo is associated with low levels of high-density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I. J Lipid Res 1997, 38:121-131.
22. Thomsen T.F., Davidsen M., Ibsen H., Jørgensen T., Jensen G., Borch-Johnsen K. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovasc Risk 2001, 8:291-297.
23. Dallongeville J., Grupposo M.C., Cottel D., et al. Association between the metabolic syndrome and parental history of premature cardiovascular disease. Eur Heart J 2006, 27:722-728.
24. Vaughan A.M., Tang C., Oram J.F. ABCA1 mutants reveal an interdependency between lipid export function, apoA-I binding activity, and Janus kinase 2 activation. J Lipid Res 2009, 50:285-292.
25. Clee S.M., Zwinderman A.H., Engert J.C., et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 2001, 103:1198-1205.
26. (P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers. J Lipid Res 1999, 40:486-494.
27. Sorci-Thomas M., Kearns M.W., Lee J.P. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. J Biol Chem 1993, 268:21403-21409.